INSUBCONTINENT EXCLUSIVE:
Novo Nordisk, the Danish pharmaceutical leader, announced a R$6.4 billion ($1.12 billion) investment in its Montes Claros facility in Minas
Silva and other top officials
The investment will add 74,000 square meters to the site, with operations in the new section expected to launch by 2028.Novo Nordisk plans
to create 600 new jobs, adding to its current workforce of over 2,000 employees in Brazil
In October 2024, the company allocated R$864 million ($152 million) to modernize insulin production and implement sustainability
projects.Novo Nordisk Commits $1.12 Billion to Expand Ozempic Production in Brazil
(Photo Internet reproduction)Two months later, it injected another R$500 million ($88 million) into enzyme production for semaglutide-based
drugs like Ozempic and Wegovy
Brazilian firms like EMS are already developing generic versions of semaglutide, while Eli Lilly plans to introduce its rival drug Mounjaro
this year.Despite uncertainties about pricing and production specifics at the expanded facility, Novo Nordisk emphasizes that this
